These changes in access and technology have led to a similarly intense increase over the last 10 years in the number of laboratories offering clinical genetic testing of BRCA1/BRCA2 specifically, multi-gene cancer gene panels for germline and somatic variant analysis, as well as companies that offer whole-exome and whole-genome studies that capture mutation information on these genes. This evidence concerns the gene BRCA2 and cancer.